Premium
Apolipoprotein E ε2 does not increase risk of early‐onset sporadic Alzheimer's disease
Author(s) -
Scott W. K.,
Saunders A. M.,
Gaskell P. C.,
Locke P. A.,
Growdon J. H.,
Farrer L. A.,
Auerbach S. A.,
Roses A. D.,
Haines J. L.,
PericakVance M. A.
Publication year - 1997
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410420317
Subject(s) - disease , medicine , apolipoprotein e , alzheimer's disease , early onset alzheimer's disease , age of onset , degenerative disease , oncology
Abstract We examined the association of apolipoprotien E (ApoE) genotype and the risk of early‐onset Alzheimer's disease (AD) in 209 white early‐onset sporadic cases (43% male) and 303 white controls (48% male) of similar age distribution. The risk of AD was significantly increased, relative to the 3/3 genotype, in people with the 4/4, 3/4, and 2/4 genotypes, controlling for age at time of examination and sex. The 2/3 genotype reduced slightly the risk of AD, although the effect was not statistically significant. We conclude, contrary to some previous reprots, that the ApoE ε2 allele does not increase the risk of early‐onset sporadic AD.